vs

Side-by-side financial comparison of Copart (CPRT) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Copart is the larger business by last-quarter revenue ($1.2B vs $622.0M, roughly 1.9× Royalty Pharma plc). Copart runs the higher net margin — 35.0% vs 34.4%, a 0.5% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 0.7%). Over the past eight quarters, Copart's revenue compounded faster (6.4% CAGR vs 4.6%).

Copart, Inc. is a multinational provider of online vehicle auction and remarketing services to automotive resellers such as insurance, rental car, fleet, and finance companies in 11 countries: the US, Canada, the UK, Germany, Ireland, Brazil, Spain, UAE, Bahrain, Oman, and Finland. Headquartered in Dallas, Texas, Copart has more than 200 physical locations, where it houses more than 10,000 acres of vehicle inventory.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

CPRT vs RPRX — Head-to-Head

Bigger by revenue
CPRT
CPRT
1.9× larger
CPRT
$1.2B
$622.0M
RPRX
Growing faster (revenue YoY)
RPRX
RPRX
+4.1% gap
RPRX
4.8%
0.7%
CPRT
Higher net margin
CPRT
CPRT
0.5% more per $
CPRT
35.0%
34.4%
RPRX
Faster 2-yr revenue CAGR
CPRT
CPRT
Annualised
CPRT
6.4%
4.6%
RPRX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CPRT
CPRT
RPRX
RPRX
Revenue
$1.2B
$622.0M
Net Profit
$403.7M
$214.2M
Gross Margin
Operating Margin
37.3%
62.4%
Net Margin
35.0%
34.4%
Revenue YoY
0.7%
4.8%
Net Profit YoY
11.5%
2.9%
EPS (diluted)
$0.41
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CPRT
CPRT
RPRX
RPRX
Q4 25
$1.2B
$622.0M
Q3 25
$1.1B
$609.3M
Q2 25
$1.2B
$578.7M
Q1 25
$1.2B
$568.2M
Q4 24
$1.1B
$593.6M
Q3 24
$1.1B
$564.7M
Q2 24
$1.1B
$537.3M
Q1 24
$1.0B
$568.0M
Net Profit
CPRT
CPRT
RPRX
RPRX
Q4 25
$403.7M
$214.2M
Q3 25
$396.4M
$288.2M
Q2 25
$406.6M
$30.2M
Q1 25
$387.4M
$238.3M
Q4 24
$362.1M
$208.2M
Q3 24
$322.6M
$544.0M
Q2 24
$382.3M
$102.0M
Q1 24
$325.6M
$4.8M
Operating Margin
CPRT
CPRT
RPRX
RPRX
Q4 25
37.3%
62.4%
Q3 25
36.7%
70.1%
Q2 25
37.3%
36.3%
Q1 25
36.6%
94.0%
Q4 24
35.4%
60.9%
Q3 24
33.6%
Q2 24
38.8%
50.2%
Q1 24
37.2%
-13.0%
Net Margin
CPRT
CPRT
RPRX
RPRX
Q4 25
35.0%
34.4%
Q3 25
35.2%
47.3%
Q2 25
33.6%
5.2%
Q1 25
33.3%
41.9%
Q4 24
31.6%
35.1%
Q3 24
30.2%
96.3%
Q2 24
33.9%
19.0%
Q1 24
31.9%
0.8%
EPS (diluted)
CPRT
CPRT
RPRX
RPRX
Q4 25
$0.41
$0.49
Q3 25
$0.40
$0.67
Q2 25
$0.42
$0.07
Q1 25
$0.40
$0.55
Q4 24
$0.37
$0.46
Q3 24
$0.34
$1.21
Q2 24
$0.39
$0.23
Q1 24
$0.33
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CPRT
CPRT
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$9.6B
$9.7B
Total Assets
$10.6B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CPRT
CPRT
RPRX
RPRX
Q4 25
$618.7M
Q3 25
$938.9M
Q2 25
$631.9M
Q1 25
$1.1B
Q4 24
$929.0M
Q3 24
$950.1M
Q2 24
$1.8B
Q1 24
$843.0M
Total Debt
CPRT
CPRT
RPRX
RPRX
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$0
$7.6B
Q2 24
$427.0K
$7.6B
Q1 24
$453.0K
$6.1B
Stockholders' Equity
CPRT
CPRT
RPRX
RPRX
Q4 25
$9.6B
$9.7B
Q3 25
$9.2B
$9.6B
Q2 25
$8.8B
$9.5B
Q1 25
$8.3B
$9.8B
Q4 24
$7.9B
$10.3B
Q3 24
$7.5B
$10.3B
Q2 24
$7.2B
$9.8B
Q1 24
$6.8B
$9.9B
Total Assets
CPRT
CPRT
RPRX
RPRX
Q4 25
$10.6B
$19.6B
Q3 25
$10.1B
$19.3B
Q2 25
$9.7B
$18.3B
Q1 25
$9.2B
$17.6B
Q4 24
$8.9B
$18.2B
Q3 24
$8.4B
$18.0B
Q2 24
$8.0B
$17.7B
Q1 24
$7.6B
$16.1B
Debt / Equity
CPRT
CPRT
RPRX
RPRX
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.00×
0.74×
Q2 24
0.00×
0.78×
Q1 24
0.00×
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CPRT
CPRT
RPRX
RPRX
Operating Cash FlowLast quarter
$535.3M
$827.1M
Free Cash FlowOCF − Capex
$427.2M
FCF MarginFCF / Revenue
37.0%
Capex IntensityCapex / Revenue
9.4%
Cash ConversionOCF / Net Profit
1.33×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$1.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CPRT
CPRT
RPRX
RPRX
Q4 25
$535.3M
$827.1M
Q3 25
$438.5M
$702.6M
Q2 25
$700.9M
$364.0M
Q1 25
$178.1M
$596.1M
Q4 24
$482.3M
$742.5M
Q3 24
$439.2M
$703.6M
Q2 24
$496.3M
$658.2M
Q1 24
$161.8M
$664.6M
Free Cash Flow
CPRT
CPRT
RPRX
RPRX
Q4 25
$427.2M
Q3 25
$350.8M
Q2 25
$572.9M
Q1 25
$61.5M
Q4 24
$245.5M
Q3 24
$301.3M
Q2 24
$408.5M
Q1 24
$38.8M
FCF Margin
CPRT
CPRT
RPRX
RPRX
Q4 25
37.0%
Q3 25
31.2%
Q2 25
47.3%
Q1 25
5.3%
Q4 24
21.4%
Q3 24
28.2%
Q2 24
36.2%
Q1 24
3.8%
Capex Intensity
CPRT
CPRT
RPRX
RPRX
Q4 25
9.4%
Q3 25
7.8%
Q2 25
10.6%
Q1 25
10.0%
Q4 24
20.6%
Q3 24
12.9%
Q2 24
7.8%
Q1 24
12.1%
Cash Conversion
CPRT
CPRT
RPRX
RPRX
Q4 25
1.33×
3.86×
Q3 25
1.11×
2.44×
Q2 25
1.72×
12.06×
Q1 25
0.46×
2.50×
Q4 24
1.33×
3.57×
Q3 24
1.36×
1.29×
Q2 24
1.30×
6.45×
Q1 24
0.50×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CPRT
CPRT

Services$952.1M82%
Other$203.0M18%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons